Denna webbsida är endast avsedd för läkare och sjukvårdspersonal med förskrivningsrätt.

DENNA WEBBPLATS ANVÄNDER KAKOR (COOKIES). Vi använder kakor för att kunna ge dig en bra upplevelse när du besöker vår webbplats. Kakor används för webbstatistik för att kunna göra förbättringar på webbplatsen. Läs mer om vår cookie policy. Du kan välja att godkänna att vi använder kakor under ditt besök genom att klicka på “Jag godkänner”.

Höga doser av ADHD-medicin ökar risken för psykos och mani

Neurosciencenews.com

12 sep 2024

Vuxna som tar höga doser av amfetaminbaserade mediciner för ADHD, såsom Adderall, löper en fem gånger högre risk att utveckla psykos eller mani. Risken var högst för de som tog 30 mg eller mer av dextroamfetamin, och 81 % av fallen med psykos eller mani kunde potentiellt ha undvikits genom att sänka dosen.

Tidigare forskning har kopplat stimulansmedel till dessa risker, men denna studie betonar vikten av doseringen. Läkare uppmanas att noggrant övervaka patienter, särskilt de som har högre risk för psykisk ohälsa.

Viktiga fakta:

  • Höga doser av ADHD-mediciner kan öka risken för psykos eller mani fem gånger.
  • 81 % av psykos- eller manifallen kunde ha förhindrats med lägre doser.
  • Metylfenidat (Ritalin) visade inte en liknande ökning av risken för psykos

Upptäckterna kommer från forskare vid McLean Hospital. Studien leddes av Lauren Moran, MD, som är forskare inom farmakoepidemiologi vid McLean Hospital. Studien publicerades den 12 september i American Journal of Psychiatry.

Forskningen granskade elektroniska patientjournaler från Mass General Brigham mellan 2005 och 2019 och analyserade risken för psykos eller mani bland personer som tog amfetaminbaserade läkemedel som Adderall, särskilt vid högre doser. Moran och hennes team fannatt 81 % av psykos- eller manifallen kunde ha undvikits med lägre doser. Forskningen finansierades av en anslag från National Institute of Mental Health (NIMH).

Studien bygger på kliniska observationer som Moran tidigare gjort som psykiater, där patienter med första episoder av psykos ofta hade förskrivits höga doser av stimulansmedel.

 

 

Artikel publicerad på Neurosciencenews.com:

Summary: Adults taking high doses of amphetamine-based medications for ADHD, such as Adderall, face a five-fold increased risk of developing psychosis or mania. The risk was highest for those taking 30 mg or more of dextroamphetamine, with 81% of psychosis or mania cases potentially avoidable by lowering the dose.

While previous research linked stimulants to these risks, this study highlights the importance of dosage. Doctors are urged to monitor patients closely, especially those at higher risk for mental health issues.

Key facts: 

  • High doses of ADHD meds can increase the risk of psychosis or mania five-fold.
  • 81% of psychosis or mania cases could have been prevented with lower doses.
  • Methylphenidate (Ritalin) did not show a similar increase in psychosis risk.

Source: McLean Hospital

Prescribing rates for stimulants that treat attention-deficit/hyperactivity disorder (ADHD) have increased significantly over the past decade, with some of the largest increases reported during the COVID-19 pandemic.

A new study of adult emergency department admissions at Mass General Brigham, led by McLean Hospital researchers, found that individuals who are taking high doses of amphetamine (e.g. Adderall) face more than a five-fold increased risk for developing psychosis or mania.

Findings were published September 12th in the American Journal of Psychiatry.

Overall, individuals with past-month prescription amphetamine use had a greater likelihood of new-onset psychosis or mania than individuals without past-month use. The risk was highest in those taking 30 mg or more of dextroamphetamine (which corresponds to 40 mg of Adderall), according to the study.

Previous studies have linked stimulants to psychosis and mania risk; however, information had been lacking on whether dosing impacted risk.

“Stimulant medications don’t have an upper dose limit on their labels, and our results show that it is clear that dose is a factor in psychosis risk and should be a chief consideration when prescribing stimulants,” said lead st

udy author Lauren Moran, MD, a pharmacoepidemiology researcher at McLean Hospital. “This is a rare but serious side effect that should be monitored by both patients and their doctors whenever these medications are prescribed.”

Moran said the study was born out of her past clinical observations as an inpatient psychiatrist. She and her McLean colleagues would regularly see patients coming in experiencing first episodes of psychosis, and their medical records would reveal they were prescribed high doses of stimulants by their doctors.

Researchers reviewed electronic health records of Mass General Brigham patient encounters between 2005 and 2019, focusing on adults aged 16 to 35, the typical age of onset for psychosis and schizophrenia. All patients were admitted to McLean Hospital following referrals from other hospitals in the Mass General Brigham healthcare system.

The researchers identified 1,374 cases of individuals presenting with first-episode psychosis or mania, compared to 2,748 control patients with a psychiatric hospitalization for other conditions like depression or anxiety.

They conducted a comparison analysis of stimulant use over the preceding month and accounted for other factors, including substance use, in order to isolate the effects of stimulants.

They found the attributable risk percentage among those exposed to any prescription amphetamine was nearly 63% and for high dose amphetamine was 81%. These findings suggest that among people who take prescription amphetamine, 81% of cases of psychosis or mania could have been eliminated if they were not on the high dose.

While a significant dose-related risk increase was seen in patients taking high doses of amphetamine, no significant risk increase was seen with methylphenidate (Ritalin) use, which is consistent with previous research, including a 2019 study led by Moran.

While the study does not prove causality, the researchers note there is a plausible biological mechanism in neurobiological changes that include a release of higher levels of the neurotransmitter dopamine from amphetamines, that parallel dopaminergic changes observed in psychosis.

Limitations of the study include inconsistencies with how electronic health records are kept. Additionally, with the research taking place in a psychiatric hospital in the Boston area that sees many patients with psychosis, it may make these findings less generalizable to other parts of the country.

Moran said the findings need not create alarm but should lead to extra caution when these medications are prescribed, especially for those who have risk factors for psychosis and mania.

“There’s limited evidence that prescription amphetamines are more effective in high doses,” said Moran. “Physicians should consider other medications our study found to be less risky, especially if a patient is at high risk for psychosis or mania.”

Authorship: In addition to Moran, Mass General Brigham co-authors included Joseph P. Skinner, BA (BWH), Ann K. Shinn MD, MPH (McLean), Kathryn Nielsen (McLean), Vinod Rao, MD, PhD (MGH), Trevor Taylor, MD, MPH (MGH), Talia R. Cohen (McLean), Cemre Erkol, MD (McLean), Jaisal Merchant, MA (McLean), Christin A. Mujica, MA (McLean), Roy H. Perlis, MD, MSc, (MGH) and Dost Ongur, MD, PhD (McLean).

Funding: This work was funded by a grant from the National Institute of Mental Health (NIMH), R01 MH122427.

The image is credited to Neuroscience News